| Literature DB >> 35963896 |
Anton Spadar1, Jody Phelan1, Rita Elias2, Ana Modesto2, Cátia Caneiras3, Cátia Marques4, Luís Lito5, Margarida Pinto6, Patrícia Cavaco-Silva7,8, Helena Ferreira9, Constança Pomba10, Gabriela J Da Silva11, Maria José Saavedra12, José Melo-Cristino5,13, Aida Duarte7,14, Susana Campino1, João Perdigão2, Taane G Clark15,16.
Abstract
Klebsiella pneumoniae (Kp) bacteria are an increasing threat to public health and represent one of the most concerning pathogens involved in life-threatening infections and antimicrobial resistance (AMR). To understand the epidemiology of AMR of Kp in Portugal, we analysed whole genome sequencing, susceptibility testing and other meta data on 509 isolates collected nationwide from 16 hospitals and environmental settings between years 1980 and 2019. Predominant sequence types (STs) included ST15 (n = 161, 32%), ST147 (n = 36, 7%), ST14 (n = 26, 5%) or ST13 (n = 26, 5%), while 31% of isolates belonged to STs with fewer than 10 isolates. AMR testing revealed widespread resistance to aminoglycosides, fluoroquinolones, cephalosporins and carbapenems. The most common carbapenemase gene was blaKPC-3. Whilst the distribution of AMR linked plasmids appears uncorrelated with ST, their frequency has changed over time. Before year 2010, the dominant plasmid group was associated with the extended spectrum beta-lactamase gene blaCTX-M-15, but this group appears to have been displaced by another carrying the blaKPC-3 gene. Co-carriage of blaCTX-M and blaKPC-3 was uncommon. Our results from the largest genomics study of Kp in Portugal highlight the active transmission of strains with AMR genes and provide a baseline set of variants for future resistance monitoring and epidemiological studies.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35963896 PMCID: PMC9375070 DOI: 10.1038/s41598-022-17996-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Baseline characteristics for the 509 K. pneumoniae study isolates.
| Characteristic | N | % |
|---|---|---|
| Centre | 20 | 3.9 |
| South | 428 | 84.1 |
| North | 61 | 12.0 |
| 1980–1982 | 46 | 9.0 |
| 1990–1999 | 13 | 2.6 |
| 2000–2009 | 169 | 33.2 |
| 2010–2019 | 281 | 55.2 |
| ST15 | 161 | 31.6 |
| ST147 | 36 | 7.1 |
| ST13 | 26 | 5.1 |
| ST14 | 26 | 5.1 |
| ST348 | 22 | 4.3 |
| ST307 | 20 | 3.9 |
| ST11 | 19 | 3.7 |
| ST231 | 16 | 3.1 |
| ST70 | 16 | 3.1 |
| ST45 | 12 | 2.4 |
| Other** | 155 | 30.5 |
| O1 | 329 | 64.6 |
| O2 | 112 | 22.0 |
| O3b | 17 | 3.3 |
| O4 | 13 | 2.6 |
| O5 | 13 | 2.6 |
| OL101 | 12 | 2.4 |
| Unknown | 10 | 2.0 |
| O3/O3a | 3 | 0.6 |
| KL24 | 96 | 16.7 |
| KL112 | 71 | 14.8 |
| KL64 | 35 | 7.1 |
| KL62 | 32 | 6.4 |
| KL3 | 26 | 5.6 |
| Other | 249 | 49.4 |
| None | 395 | 77.6 |
| KPC-3 | 101 | 19.8 |
| OXA-181 | 6 | 1.2 |
| GES-5; KPC-3 | 5 | 1.0 |
| OXA-48 | 1 | 0.2 |
| GES-5 | 2 | 0.4 |
| NDM-1 | 2 | 0.4 |
| AAC(3)-II; APH(3')-I; APH(6)-I; | 154 | 30.3 |
| AAC(6')-I; ANT(3'')-I; APH(3')-I; APH(6)-I; | 64 | 12.6 |
| APH(3')-I; APH(6)-I; | 33 | 6.5 |
| AAC(3)-II; ANT(3'')-I; APH(3')-I; APH(6)-I; | 30 | 5.9 |
| ANT(3'')-I; | 26 | 5.1 |
| AAC(3)-II; AAC(6')-I; ANT(3'')-I; APH(3')-I; APH(6)-I; | 24 | 4.7 |
| AAC(3)-II; | 19 | 3.7 |
| AAC(6')-I; ANT(3'')-I; | 18 | 3.5 |
| AAC(3)-II; AAC(6')-I; ANT(3'')-I; | 10 | 2.0 |
| ANT(3'')-I; APH(3')-I; APH(6)-I; | 9 | 1.8 |
| AAC(3)-II; ANT(3'')-I; | 8 | 1.6 |
| AAC(3)-II; ANT(3'')-I; APH(3')-I; | 8 | 1.6 |
| AAC(3)-II; APH(3')-I; | 8 | 1.6 |
**Includes ST1138 with 7 isolates.
Figure 1Phylogenetic trees of the most commons sequence types (STs), their antimicrobial resistance (AMR) phenotype, and carbapenemase and ESBL genotypic profiles. K-Loci refer to inferred K serotypes. Branch colours represent bootstrap support values.
Figure 2The most common ESBL (bla) and carbapenemase (bla) genes across the 509 Kp isolates by year group.
Figure 3(A) Clustering of isolates by their plasmid replicon (replicon clusters, RC) and antimicrobial resistance (AMR) genotypic profiles, revealing differentiation by carriage of blaKPC-3 and blaCTX-M-15 genes. X and Y axis are dimensions on which full data is projected, they are unitless; (B) Abundance of isolates from different plasmid clusters.
Figure 4Distribution of inhibition zone diameters for different genotypes for (A) imipenem, (B) cefotaxime, (C) cefoxitin, (D) ciproflocaxin, and (E) gentamicin antimicrobials.